Premature ventricular contraction laboratory findings: Difference between revisions
Homa Najafi (talk | contribs) /* 2017 AHA/ACC/HRS Guideline for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death (DO NOT EDIT){{cite journal|last1=Al-Khatib|first1=Sana M.|last2=Stevenson|first2=William G.|last3=Ackerman|first3=Michael... |
Homa Najafi (talk | contribs) /* 2017 AHA/ACC/HRS Guideline for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death (DO NOT EDIT){{cite journal|last1=Al-Khatib|first1=Sana M.|last2=Stevenson|first2=William G.|last3=Ackerman|first3=Michael... |
||
| Line 22: | Line 22: | ||
| colspan="1" style="text-align:center; background:LemonChiffon"|[[ESC guidelines classification scheme#Classification of Recommendations|Class IIa]] | | colspan="1" style="text-align:center; background:LemonChiffon"|[[ESC guidelines classification scheme#Classification of Recommendations|Class IIa]] | ||
|- | |- | ||
|bgcolor="LemonChiffon" |<nowiki></nowiki>'''1.''' In patients with structural heart disease, measurement of natriuretic peptides (BNP or N-terminal pro-BNP) can be useful by adding prognostic information to standard risk factors for predicting SCD or SCA ''([[ACC AHA Guidelines Classification Scheme#Level of Evidence|Level of Evidence: B-NR]]).''<nowiki/> | |bgcolor="LemonChiffon" |<nowiki></nowiki>'''1.''' In patients with structural heart disease, measurement of natriuretic peptides (BNP or N-terminal pro-BNP) can be useful by adding prognostic information to standard risk factors for predicting SCD or SCA ''([[ACC AHA Guidelines Classification Scheme#Level of Evidence|Level of Evidence: B-NR]]).''<ref name="ScottBarry2009">{{cite journal|last1=Scott|first1=Paul A.|last2=Barry|first2=James|last3=Roberts|first3=Paul R.|last4=Morgan|first4=John M.|title=Brain natriuretic peptide for the prediction of sudden cardiac death and ventricular arrhythmias: a meta-analysis|journal=European Journal of Heart Failure|volume=11|issue=10|year=2009|pages=958–966|issn=13889842|doi=10.1093/eurjhf/hfp123}}</ref> | ||
<nowiki/> | |||
|- | |- | ||
|} | |} | ||
Revision as of 15:50, 16 April 2020
|
Premature ventricular contraction Microchapters |
|
Differentiating Premature Ventricular Contraction from other Disorders |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Premature ventricular contraction laboratory findings On the Web |
|
FDA on Premature ventricular contraction laboratory findings |
|
Premature ventricular contraction laboratory findings in the news |
|
Blogs on Premature ventricular contraction laboratory findings |
|
to Hospitals Treating Premature ventricular contraction laboratory findings |
|
Risk calculators and risk factors for Premature ventricular contraction laboratory findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mugilan Poongkunran M.B.B.S [2]
Overview
Many cases of premature ventricular contraction have no definite cause, it may be the result of various other problems. If PVC patients present with symptoms, a generalized approach is done to find the precipitating factors.
Laboratory Findings
The following investigations are done to patients with symptoms :
- Renal function and electrolytes
- Complete blood count
- ABG : To rule out hypercapnia and hypoxia.
- Thyroid-stimulating hormone : To rule out hyperthyroidism and of relevance if amiodarone is administered for treatment.
2017 AHA/ACC/HRS Guideline for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death (DO NOT EDIT)[1]
Recommendation for Biomarkers
| Class IIa |
| 1. In patients with structural heart disease, measurement of natriuretic peptides (BNP or N-terminal pro-BNP) can be useful by adding prognostic information to standard risk factors for predicting SCD or SCA (Level of Evidence: B-NR).[2]
|
References
- ↑ Al-Khatib, Sana M.; Stevenson, William G.; Ackerman, Michael J.; Bryant, William J.; Callans, David J.; Curtis, Anne B.; Deal, Barbara J.; Dickfeld, Timm; Field, Michael E.; Fonarow, Gregg C.; Gillis, Anne M.; Granger, Christopher B.; Hammill, Stephen C.; Hlatky, Mark A.; Joglar, José A.; Kay, G. Neal; Matlock, Daniel D.; Myerburg, Robert J.; Page, Richard L. (2018). "2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death". Circulation. 138 (13). doi:10.1161/CIR.0000000000000549. ISSN 0009-7322.
- ↑ Scott, Paul A.; Barry, James; Roberts, Paul R.; Morgan, John M. (2009). "Brain natriuretic peptide for the prediction of sudden cardiac death and ventricular arrhythmias: a meta-analysis". European Journal of Heart Failure. 11 (10): 958–966. doi:10.1093/eurjhf/hfp123. ISSN 1388-9842.